Trial Details
COMPLETEDBasic Information
| Clinical ID | c4739 |
|---|---|
| Identifier | NCT00040521 |
| Trial Title | Study Evaluating rhIL-11 in Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn Disease|Inflammatory Bowel Disease |
| Interventions | DRUG: Recombinant Human Interleukin-11 (rhIL-11) |
Participant Information
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
|---|---|
| City | Arvada |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2002-04 |
|---|---|
| Primary Completion Date | 2003-10 |
| Completion Date | 2003-10 |